| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.072 | 0.06 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.06 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.06 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | -0.069 | 0.06 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.065 | 0.06 |